Company Overview - The company was listed on the Beijing Stock Exchange on February 9, 2023[4]. - The total share capital of the company is 70,861,250 shares, with no preferred shares issued[19]. - The actual controllers of the company include Zhang Aijiang and several family members, ensuring a stable management structure[20]. - The company operates primarily in the pharmaceutical manufacturing industry, focusing on chemical raw materials and traditional Chinese medicine[19]. - The company has not faced any delisting risks as per the latest report[10]. Financial Performance - The revenue for the first half of 2023 reached 67,590,000 RMB, with a sales volume of 10,815,000 RMB and total tax contributions of 7,946,000 RMB[4]. - The company achieved operating revenue of ¥123,359,358.17, representing a growth of 19.89% compared to the same period last year[26]. - Net profit attributable to shareholders reached ¥30,480,652.04, an increase of 32.98% year-on-year[26]. - Operating revenue rose by 19.89% to ¥123,359,358.17, compared to ¥102,894,752.83 in the previous year[43]. - Net profit increased by 34.88% to ¥30,826,161.10, compared to ¥22,854,181.63 in the same period last year[43]. - The company's gross profit margin improved to 48.45%, up from 45.58% in the same period last year[26]. - The company's cash flow from operating activities was ¥15,115,039.82, a decrease of 52.75% compared to the previous year[28]. - The company reported a net non-recurring profit of ¥1,861,601.22 after tax[31]. Assets and Liabilities - The total assets of the company amounted to 1.6 billion RMB as of 2022[4]. - Total assets at the end of the reporting period amounted to ¥502,953,543.58, reflecting a growth of 42.13% from the end of the previous year[27]. - Net assets attributable to shareholders increased to ¥455,400,015.67, up 63.52% compared to the previous year-end[27]. - The company's total liabilities decreased to CNY 43,018,266.61 from CNY 71,186,539.18, a reduction of about 39.5%[108]. - The company's equity attributable to shareholders increased to CNY 455,400,015.67 from CNY 278,499,029.84, showing a growth of approximately 63.7%[108]. Research and Development - The company has 206 drug registration approvals and 68 patents, demonstrating its capacity for high-quality drug production[32]. - Research and development expenses grew by 33.65% to ¥5,201,297.60, reflecting the company's commitment to innovation[43]. - The company continues to focus on technological and management innovation to enhance core competitiveness[36]. Market and Product Development - The company's product, Vitamin C Chewable Tablets, was awarded the "Jiangxi Famous Brand Product" by the Jiangxi Brand Construction Promotion Association in June 2023[4]. - The company plans to expand its market presence and enhance its product offerings in the pharmaceutical sector[8]. - The company reported a significant increase in sales for its traditional Chinese medicine products, with sales reaching 22,625,000 RMB in 2022, up from 8,359,000 RMB in 2020[4]. Shareholder Information - The largest shareholder, Zhang Aijiang, holds 34,857,012 shares, representing 49.1905% of the total shares[80]. - The total number of shareholders holding more than 5% of shares is 10, with a combined holding of 75.4755%[80]. - The company has not engaged in any significant related party transactions during the reporting period[71]. Corporate Governance - The company has established a comprehensive internal control system to mitigate risks associated with governance and compliance as its operations expand[65]. - The company has maintained a stable management team with no significant changes in directors or independent directors[97]. - The company appointed Cheng Shuping as the new Chief Financial Officer on June 29, 2023[98]. Investment and Fundraising - The company raised a total of RMB 161,358,750.00 through the issuance of 17,075,000 shares at a price of RMB 9.45 per share for the production of traditional Chinese medicine health products[85]. - The total net amount raised from the 2023 public offering is RMB 16,413.56 million, with RMB 2,316.25 million already invested in various projects[89]. - The company has no plans to change the use of raised funds or to supplement working capital with idle funds[88]. Risk Management - The company faces risks related to the transition of raw material drug approvals to a filing system, which may lead to increased competition and potential revenue impact[64]. - Direct materials account for a significant portion of production costs, making the company vulnerable to price fluctuations and supply stability issues[64]. - The company has implemented measures to control product quality risks, including advanced technology and modern management practices[65]. Accounting and Financial Reporting - The company adheres to the accounting standards, ensuring that financial statements accurately reflect its financial position, operating results, and cash flows[157]. - The company has not changed its accounting policies or estimates compared to the previous financial year[141]. - The financial statements reflect the results of subsidiaries from the date control is obtained, with adjustments made to the comparative figures accordingly[171].
新赣江(873167) - 2023 Q2 - 季度财报